BioCorteX

Drug Discovery · Biotechnology
Data updated Nov 20, 2026Money ledger: 1 record from 1 sourceAnnounced 1Full reportReport a mistake

Facts

as of Nov 20, 2026

BioCorteX runs in-silico bridge trials that map how the microbiome changes a drug.

Employees
11-50estimated range

These are the key facts about BioCorteX on Alion as of Nov 20, 2026. The latest round is Venture - Series Unknown of $5M, announced in 2023.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

BioCorteX has $5M paid in by investors, lenders and donors.

$5MPaid in
Money innewest first
Equity raised
Mar 2023 · Venture round
$5MPaid
Money by yearUSD, rounds and grants
2023$5M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Sources name Sofinnova Partners, Hoxton Ventures among the owners or investors of BioCorteX.

Named investors, no share stated2
Holders and shares as each register or filing states them.

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Milestones

Each milestone is dated by its source: registers, filings, the press